Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression

Higano, Celestia S.; Shields, Andrew; Wood, Nathanael; Brown, Judy; Tangen, Cathy

doi:10.1016/j.urology.2004.07.019

Cited by 92 publications

(78 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…38 Whether intermittent ADT may attenuate this bone loss remains controversial. 7 In longitudinal studies, 5.7-8.5% decreases in lumbar spine cancellous bone mineral (using QCT) 4,11,12 and 1.8 -2.3% decreases in femoral neck BMD (using DXA) 6,7,9 -15 were recorded after 12 months of ADT. In the same longitudinal studies, bone loss as measured using spinal DXA was less severe, varying from 2.0% to 4.6%, with greater loss seen in younger men due to the absence of confounding variables that involved the spine.…”

Section: Bmd Changes In Normal Men and In Men With Prostate Carcinomamentioning

confidence: 97%

Osteoporosis in men with prostate carcinoma receiving androgen‐deprivation therapy

Diamond

Higano

Smith

et al. 2004

Cancer

242

View full text Add to dashboard Cite

BACKGROUNDAndrogen‐deprivation therapy (ADT) is prescribed with increasing frequency for men with prostate carcinoma. There is growing concern about the effects of such therapy on the skeleton. In the current review, the authors addressed the current research, diagnostic methods, and treatment recommendations for bone loss and osteoporosis in men with prostate carcinoma who received ADT.METHODSData were obtained from electronic literature searches (for the years 1986 through 2002) and from abstracts and meeting proceedings. All randomized and nonrandomized clinical trials, retrospective studies, and cross‐sectional studies of osteoporosis in men with prostate carcinoma who received ADT with or without other therapies were reviewed.RESULTSThe findings confirmed that ADT resulted in significant bone loss in men with prostate carcinoma. Bone mineral density (BMD) of the hip, as measured by dual‐energy X‐ray absorptiometry (DXA), is considered the preferred site of assessment in older men. Spinal BMD is equally important, although careful interpretation of spinal DXA values is required, because of coexisting facet joint disease and extravertebral calcification. Osteoporosis is diagnosed when BMD is > 2.5 standard deviations below a reference mean. Men with prostate carcinoma who were treated with ADT had average BMD measurements below those of eugonadal men. Rates of bone loss ranged from 2% to 8% in the lumbar spine and from 1.8% to 6.5% in the femoral neck during the initial 12 months of continuous ADT. Retrospective data indicated an increased risk of fracture in men with prostate carcinoma who were treated with ADT.CONCLUSIONSFor men with prostate carcinoma who are at high risk for osteoporosis and fractures, clinical management should be dictated by the results of radiographic and DXA skeletal assessment. Cancer 2004;100:892–9. © 2004 American Cancer Society.

show abstract

Section: Bmd Changes In Normal Men and In Men With Prostate Carcinomamentioning

confidence: 97%

Osteoporosis in men with prostate carcinoma receiving androgen‐deprivation therapy

Diamond

Higano

Smith

et al. 2004

Cancer

242

View full text Add to dashboard Cite

show abstract

“…[21][22][23][24][25][26][27] All adverse events associated with perprotocol treatment are shown in Table S3 in the Supplementary Appendix. The early diagnosis of failure of definitive treatment, as determined according to the PSA level, subjects otherwise asymptomatic men to many years of androgen deprivation, adversely affecting their quality of life.…”

Section: Discussionmentioning

confidence: 99%

Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy

2012

N Engl J Med

View full text Add to dashboard Cite

show abstract

“…In the elderly population of prostate cancer patients increased incidence of osteoporosis and resulting bone fractures are of major concern. Higano and colleagues observed loss of bone mineral density during 9 months of androgen suppression significantly greater than the expected 0.5%-1% annual loss in IAS; however, interruption of androgen suppression attenuated the rate of bone loss without full recovery (Higano, et al, 2004). In the study by Malone and colleagues, general loss of potency occurred during the treatment period, but was regained by half of the evaluable patients when therapy was withdrawn (Malone, et al, 2005).…”

Section: Side Effects Of Androgen Suppression Therapymentioning

confidence: 93%

Intermittent Androgen Suppression Therapy for Prostate Cancer Patients: A Choice for Improved Quality of Life?

Hamilton¹,

Olszewski-Hamilton²,

Theyer³

2011

Prostate Cancer - Diagnostic and Therapeutic Advances

View full text Add to dashboard Cite

Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression

Cited by 92 publications

References 18 publications

Osteoporosis in men with prostate carcinoma receiving androgen‐deprivation therapy

Osteoporosis in men with prostate carcinoma receiving androgen‐deprivation therapy

Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy

Intermittent Androgen Suppression Therapy for Prostate Cancer Patients: A Choice for Improved Quality of Life?

Contact Info

Product

Resources

About